2013
Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population.
Akselrod H, Grau LE, Barbour R, Heimer R. Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population. American Journal Of Public Health 2013, 104: 1713-21. PMID: 24134382, PMCID: PMC3990658, DOI: 10.2105/ajph.2013.301357.Peer-Reviewed Original ResearchConceptsInjection drug usersHepatitis B virusDrug use durationSubstance abuse treatmentB virusRisk factorsCriminal justice involvementDrug usersAbuse treatmentAdult injection drug usersSeroprevalence of HIVInjection drug usePotential risk factorsSignificant predictorsUse durationMultiple viral infectionsEffective harm reduction strategiesHarm reduction strategiesJustice involvementHCV seroprevalenceInjection useInterim analysisViral infectionDrug useSerological tests
2012
Survival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa
Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, Master I, van der Merwe TL, Friedland GH. Survival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa. PLOS ONE 2012, 7: e31786. PMID: 22412840, PMCID: PMC3295798, DOI: 10.1371/journal.pone.0031786.Peer-Reviewed Original ResearchConceptsXDR-TB patientsDrug-resistant tuberculosisRetrospective case-control studyXDR-TB casesCommunity-based hospitalCase-control studyGlobal public healthHIV coinfectionMicrobiological correlatesModifiable factorsAvailable interventionsRural South AfricaControl studyPatientsTuberculosisPublic healthSurvivorsSurvivalDaysHospitalMortality